HAVN LIFE NATURAL HEALTH PRODUCTS NOW AVAILABLE ON AMAZON.CA
With FBA designation, the Company continues to grow its retail footprint by partnering with the world’s largest ecommerce site
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”)a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind,
is pleased to announce it has received FBA designation from Amazon.ca for the company’s new line of natural health products, which launched on June 3rd. The ecommerce giant now carries the full line of HAVN Life natural health products and ships anywhere in Canada.
“Having HAVN Life products available for purchase on Amazon.ca is a huge win for us,” says Tim Moore, CEO of HAVN Life. “The reach and scope of the platform is bar none, and we are thrilled to be visible through the Amazon network so we can help build and empower healthy communities,” he adds.
In addition to Amazon.ca, the HAVN Life natural health product line is available through their own ecommerce site, yourhavnlife.com, which ships products to both US and Canadian markets. The products are also available at Nesters Market and Choices Market retail locations throughout British Columbia. With a growing retail footprint, HAVN Life is increasing its revenue stream while reaching new markets and customers.
HAVN Life formulations are non-GMO, vegan, bioavailable, and naturally-derived from functional mushrooms and other plants and created with human optimization in mind. The natural health product line has been thoughtfully formulated with adaptogens and antioxidants to support overall brain health, with natural compounds that are proven to support memory, focus, energy, and overall cognitive function.
Connect
Investor Relations
ir@havnlife.com
(604) 687-7130
Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife
Media Contact
savi@emergence-creative.com
(647) 896-8078
HAVN LIFE SIGNS AGREEMENT TO ENABLE EXPORT OF PSILOCYBIN INTO CANADA, THE US AND EUROPE
The Agreement with P.A. Benjamin Manufacturing Company whom operates a GMP compliant facility in Jamaica
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”)a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is thrilled to announced a new agreement with P.A. Benjamin Manufacturing Company (“PAB”), a pharmaceutical manufacturing company based in Kingston, Jamaica.
PAB operates a GMP compliant facility and will be contract packing HAVN Life naturally-derived psilocybin, following the necessary protocols to allow for export from Jamaica and import into Canada, the US and Europe. Along with HAVN Life’s collaboration with Hypha Wellness, a Jamaican food and psychoactive mushroom producer, this agreement further reinforces the Company’s commitment to collaboration and long-term industry growth in Jamaica. Further building out this psychedelic supply chain puts HAVN Life in an excellent position to be an early mover, as markets begin to open up around the globe. The agreement will also open the door for HAVN Life to seek API designations, as well as secure further supply agreements with companies seeking high-quality and naturally derived psilocybin.
“As a new industry it is critical that there is stakeholder partnership and as such the partnership between Jamaican GMP manufacturer, P.A. Benjamins, Hypha Wellness, and HAVN Life Sciences is a step in the right direction” remarks Hon. Floyd Green, MP, Minister of Agriculture and Fisheries. “The sustainability of the industry will depend largely on our ability to effectively research psilocybin mushrooms and to combine Agriculture with manufacturing,” he adds.
“This partnership with PAB is absolutely key for our ability to supply safe, quality-controlled psilocybin API’s to researchers and patients around the globe,” says HAVN Life CEO, Tim Moore. “The agreement will make HAVN Life the first company in the Caribbean Community and Common Market with GMP capabilities for psilocybin—a huge step towards our goal to be at the forefront of the international psychedelic supply chain framework,” he adds.
“We’re excited and committed to work with HAVN Life Science and Hypha Wellness to export psilocybin, and build our research and development partnerships,” says Christopher Powell, Director at P.A. Benjamin Manufacturing Company.
“Working with Jamaican stakeholders and the GMP manufacturer P.A. Benjamin’s, we’re focused on developing a framework for manufacturing and exports,” says Benjamin Graeme, Founder, Director at Hypha Wellness. “It’s an exciting time as Jamaica has a unique value position in the international market, and the means to supply it,” he adds.
The agreement and packaging of psilocybin through PAB’s GMP compliant facility will be in compliance with Health Canada and local guidelines.
About HAVN Life Sciences Inc.
HAVN Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural health products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.
About P.A. Benjamin Manufacturing Company
The Benjamin Family has been a trusted name in Jamaica for over a century, established in 1879. ISO certified, the mission of P.A. Benjamin Manufacturing Company Limited is to manufacture and distribute the highest quality goods in the health care, toiletries, personal care and culinary preparations categories in both the domestic and export markets.
Increased emphasis has been placed on the export potential for its products. Benjamins has embarked on a very aggressive new products development program to complement several of the already established products, and also to venture into new product areas in synergy with the company’s capabilities. The new product development efforts are ongoing with emphasis being placed on the expansion of the pharmaceutical range of products.
Connect
Investor Relations
ir@havnlife.com
(604) 687-7130
Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife
Media Contact
savi@emergence-creative.com
(647) 896-8078
Exotic shrooms coming to a city near you
HAVN LIFE SIGNS AGREEMENT TO ENABLE EXPORT OF PSILOCYBIN INTO CANADA, THE US AND EUROPE
HAVN Life Sciences (HAVN) can now export Jamaican-grown psilocybin to Canada, the US, and Europe.
HAVN signed into an agreement with P.A. Benjamin Manufacturing Company, a Jamaican pharmaceutical company that will produce naturally-derived psilocybin at a GMP compliant facility. HAVN aims to be leader in the psychedelic supply chain by supplying researchers, patients, and companies across the globe with natural psilocybin.
HAVN LIFE SIGNS EXCLUSIVE SUPPLY AGREEMENT WITH CUBE PSYTECH
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is announcing a new supply agreement with Cube Psytech, a biopharmaceutical and biotechnology company focused on sustainable, natural medicine that is developing a proprietary line of psilocybin microdosing health products with functional and psychedelic mushrooms.
Based in Vancouver, Cube Psytech is currently raising funds for the construction and development of a Health Canada approved CGMP facility, as well as a research and development lab for product development. This agreement with Cube Psytech further adds to HAVN Life’s growing list of supply partners, leveraging the Company’s mushroom cultivation and production operations in Jamaica as a robust revenue stream.
“We are very happy to add Cube Psytech to our list of supply partners,” says HAVN Life CEO, Tim Moore. “We’ve been working tirelessly to build out a full-fledged supply chain out of our facility in Jamaica as we continue to see demand for naturally derived psilocybin products. We are ready and willing to meet this demand,” he adds.
“We’re excited to build this relationship with HAVN Life,” says Cube Psytech CEO and Co-Founder Erick Factor. “We have been looking to secure a safe and standardized supply of psilocybin for the development of our products. We feel that HAVN Life is the ideal partner to fulfill this requirement,” he adds.
The agreement and supply of psilocybin to Cube Psytech will be in compliance with Health Canada guidelines.
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer
About HAVN Life Sciences Inc.
HAVN Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural health products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.
Connect
Investor Relations
ir@havnlife.com
(604) 687-7130
Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife
Media Contact
savi@emergence-creative.com
(647) 896-8078
HAVN LIFE ANNOUNCES MANAGEMENT CHANGE
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”) announces that Mr. Gordon Clissold has joined the Company as Chief Financial Officer.
Mr. Clissold is a Chartered Professional Accountant who has been recognized for his contributions to the accounting profession. He has over 20 years of experience as an operational and financial manager, in both public and private companies, with career experience spanning technology, manufacturing, wholesale distribution, and professional services. His management competencies encompass organizational leadership, strategic planning, corporate finance, financial modelling, ERP and financial systems implementation, internal control development, and due diligence for mergers and acquisitions. Mr. Clissold has led the international expansion of companies and has established a reputation for being able to identify the talent necessary to build high-performing teams.
The Company further announces that Eli Dusenbury will remain on as a consultant providing accounting services on an as needed-basis.
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer
About HAVN Life Sciences Inc.
HAVN Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural health products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.
Connect
Investor Relations
ir@havnlife.com
(604) 687-7130
Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife
Media Contact
savi@emergence-creative.com
(647) 896-8078
HAVN LIFE SCIENCES SIGNS FINISHED GOODS SUPPLY AGREEMENT WITH ALLIED HEALTH
The Agreement will utilize HAVN Life’s fully integrated supply chain model, from the growing of psilocybin through to extraction, compounding, and encapsulation
Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is thrilled to announce it has entered into a supply agreement (the “Supply Agreement”) with Allied Health (OTCQB: ALID), an innovator in the cannabis and psychedelics space, integrating medical research, cultivation and processing, and proprietary products and natural health product distribution.
Allied Health is in the process of developing Psilonex™ RX Capsules, a proprietary formulation of psilocybin, cordyceps, lion’s mane, vitamin B, and other ingredients that will be available to their patient cohort, including more than 300 veterans, police, fire, and ambulance personnel struggling with PTSD and related mental health issues. Allied Health is currently seeking a Section 56 special access exemption for their patient cohort for the use of Psilonex™ RX Capsules, with continued research and data gathering planned for future product development.
“We are beyond excited to welcome Allied Health to our growing list of supply partners,” says HAVN Life CEO, Tim Moore. “With a supply partner roster that includes Revive Therapeutics, The Heroic Hearts Project, Health Tech Connex, ATMA and now Allied Health, we are demonstrating industry support in our business model as an end-to-end supply chain for psychedelic compounds. With plans underway to have our Vancouver facility fully licenced and operational in the near future, this new aspect of production will be a tremendous revenue opportunity for us,” he adds.
Pursuant to the Supply Agreement, Allied Health will have access to the Company’s full range of psychedelic compounds and APIs, cultivated at the Company’s facility in Jamaica, which opened this May. This Supply Agreement is a major milestone, marking the completion of HAVN Life’s vision of a fully integrated supply chain model, from the growing of psilocybin, through to extraction, compounding and finally to encapsulation.
Allied Health’s decision to use naturally derived psilocybin in their Psilonex™ RX Capsules underscores the growing patient preference for plant-based products over synthetic ones. By partnering with another industry innovator, HAVN Life further consolidates its position as an integral supply chain provider in respect of naturally-derived psychedelics for clinical providers and researchers around the globe.
With the recent news that California is moving toward decriminalizing psychedelics through Senate Bill 519 – Controlled substances: decriminalization of certain hallucinogenic substances, the growing demand for clinical and therapeutic use of psychedelic compounds is undeniable, and highlights HAVN Life’s unique position as a source of safe and standardized products.
Any transactions to be completed pursuant to the Supply Agreement, including any supply of psilocybin thereunder, will be subject to compliance with any and all applicable laws and regulations, including those of Health Canada.
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer
About HAVN Life Sciences Inc.
HAVN Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural health products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.
Connect
Investor Relations
ir@havnlife.com
(604) 687-7130
Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife
Media Contact
savi@emergence-creative.com
(647) 896-8078
HAVN LIFE ANNOUNCES RETAIL PARTNERSHIP WITH GROCER, CHOICES MARKETS
Newly-launched line of natural health products to be available at all locations later this month
Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce it has secured a product listing agreement with Choices Markets for the company’s new line of natural health products, which officially launched on June 3rd. The locally owned and operated grocery chain will carry the full line of HAVN Life natural health products at all locations. The product line is expected to hit shelves later this month.
“We are excited to have our new line of natural health products at Choices Markets,” says Tim Moore, CEO of HAVN Life. “As purveyors of natural, organic, and specialty foods, Choices Markets is aligned with our focus on health and wellness and we are thrilled to be expanding our distribution network to help build and empower healthy communities,” he adds.
Choices Markets is the second retail partner that HAVN Life has secured, as part of the company’s distribution strategy that includes retail, online and subscription channels to reach a broad customer base and deliver a quality product experience. Currently, the seven formulations are available at yourHAVNlife, and later this month through Amazon and at select Nesters Market stores in B.C.
HAVN Life formulations are non-GMO, vegan, bioavailable, naturally-derived from functional mushrooms and other plants and created with human optimization in mind. The natural health product line has been thoughtfully formulated with adaptogens and antioxidants to support overall brain health, with natural compounds that are proven to support memory, focus, energy, and overall cognitive function.
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer
About HAVN Life Sciences Inc.
HAVN Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural health products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.
Connect
Investor Relations
ir@havnlife.com
(604) 687-7130
Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife
Media Contact
savi@emergence-creative.com
(647) 896-8078
HAVN LIFE LAUNCHES NEW LINE OF NATURAL HEALTH PRODUCTS
Seven new formulations that support brain health and immune function will be available online and at select retail locations starting June 3
Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a Vancouver-based biotechnology company focused on brain health, is announcing the launch of its first retail line of natural health products. The seven SKUs—Mind Mushroom, Bacopa Brain, Rhodiola Relief, Cordyceps Perform, Chaga Immunity, Reishi Recharge and Lion’s Mane—are now available at yourHAVNlife.com and will be rolling out on Amazon and at select Nesters Market stores across British Columbia later this month.
Designed to advance HAVN Life’s mission of unlocking human performance and empowering people to reach their full potential, the formulations include a range of high-quality mushroom and plant extracts that help to boost immune function and reduce inflammation. With our growing need for solutions to improve productivity, combat daily stressors, and boost immune health, these formulations are naturally harvested and effective in supporting brain health and the capabilities of the mind.
The launch of this retail line is part of HAVN Life’s strategy of developing natural health products in parallel with their work on the standardized extraction of psychedelic compounds as a supply chain for research and clinical applications. This work is united by a vision of helping people connect with their potential, free from the stresses and imbalances that hold us back.
“With the launch of our first retail line, we are excited to enter the natural health products market,” said HAVN Life CEO Tim Moore. “The activation of our retail arm is a major milestone for the company and will enable us to build the HAVN brand as we continue researching and developing additional formulations that can help people thrive.”
Modern Science Meets Ancient Wisdom
These formulations were created by HAVN Life’s Chief Science Officer, Gary Leong, an industry veteran of 14 years who was previously Chief Scientific Officer at Jamieson Labs. Leveraging Gary’s biopharma and wellness expertise, HAVN Life retail products offer evidence-informed, high quality natural compounds that are proven to support memory, focus, energy, and overall cognitive function:
- Mind Mushroom: A source of antioxidants to fight against free radical cell damage and to balance the immune system. This formulation is an adaptogen that increases energy and resistance to stress. (CAD $54 + tax)
- Bacopa Brain: Supports brain health, improves memory and has been used for centuries in herbal medicine. Bacopa is a powerful plant extract that is clinically proven to support cognitive function and the nervous system. (CAD $27 + tax)
- Rhodiola Relief: This adaptogen provides relief from symptoms of stress, including mental fatigue. This formulation supports mental focus and stamina. (CAD $45 + tax)
- Cordyceps Perform: Cordyceps mushrooms help support a healthy immune system. Used in herbal medicine, they improve lung and kidney function and are a source of antioxidants that help fight against free radical cell damage in the body. (CAD $30 + tax)
- Chaga Immunity: Chaga mushrooms are the second highest antioxidant-rich food on the planet. This superfood helps support the immune system and control inflammation in the body. (CAD $36 + tax)
- Reishi Recharge: Supports the immune system and is used in herbal medicine around the world for energy, stress and liver function support. This multi-purpose mushroom has also been traditionally used to strengthen the heart to reduce fatigue, insomnia and appetite as well as coughs and wheezing. (CAD $30 + tax)
- Lion’s Mane: These mushrooms are packed with antioxidants and help protect against free radical cell damage. (CAD $36 + tax)
The product line uses plant-derived, non-psychoactive compounds that have been used in traditional medicine for thousands of years, and are formulated with the highest standards of extraction and quality control. The medicinal and nutritional properties of mushrooms have long been understood across cultures and modern research is now showing us that they also contain compounds that are specifically beneficial for cognitive function and help to support overall human health and wellness.
The senior leadership of HAVN Life brings decades of natural health product experience with some of the leading brands and companies in Canada. HAVN Life Executive Chairman, Vic Neufield was previously the CEO and president at Jamieson Labs, and Chief Operations Officer, Jenna Pozar has more than 18 years of marketing and logistics experience in the natural health and performance space, including with Jamieson Wellness. Along with Chief Science Officer Gary Leong, the team is well positioned to leverage its expertise and establish HAVN Life as a leader in the natural health products space.
HAVN Life’s recent acquisition of a state-of-the-art manufacturing and packaging facility in Richmond, B.C. will enable local production and rapid delivery of the product line to retailers. The site will facilitate an expanded product portfolio and, with the launch of this first retail line, is a significant step towards building a strong presence in the Canadian natural health product market.
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer
About HAVN Life Sciences Inc.
HAVN Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural health products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.
Connect
Investor Relations
ir@havnlife.com
(604) 687-7130
Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife
Media Contact
savi@emergence-creative.com
(647) 896-8078
HAVN LIFE COMPLETES ACQUISITION OF CLINICAL STAGE IP FOR DEVELOPMENT OF CLUSTER HEADACHE DRUG
The Company will seek Orphan Drug Designation to significantly reduce time to market
Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce the completion of the previously announced acquisition of clinical stage intellectual property (“IP”) from Bolt Therapeutics (the “Acquisition”). With this Acquisition, HAVN Life is working towards substantiating a patent application after which preclinical work can begin.
The IP consists of a combination of BOL-148, which has demonstrated potential for treating cluster headaches in a human study, and a neuroprotectant that is believed to act in unison with BOL-148. BOL-148, an unrestricted compound, is an analogue of LSD that does not produce the same psychotropic effects, making it a promising candidate for a new therapy.
“This acquisition opens a new chapter for HAVN Life in a clinical setting, positioning us at the forefront of the development of new and innovative therapies to support brain health,” remarked Vic Neufeld, HAVN Life’s Executive Chairman. “While our focus continues to be on building our supply chain capabilities in the psychedelic space, this acquisition demonstrates our multifaceted approach to exploring evidence-driven solutions that optimize human potential,” he added.
HAVN Life’s research team will explore ways to optimize the patient experience with the neuroprotective agent used in combination with BOL-148, which previously showed a signal of efficacy in a peer reviewed human study. The team will begin conducting preclinical studies to assess the efficacy of this combination, paving the way for future clinical trials. At the same time, HAVN Life is eager to work alongside patient advocacy groups to increase awareness of this condition—some 300,000 patients in the US suffer from cluster headaches, and about 60,000 deal with chronic pain as a result. Despite these numbers, there is only one approved treatment for the condition, making it an area of massive unmet need.
The combination of the Company’s formulation, clinical, regulatory and IP strategies is designed to expedite the time to market, reduce the clinical burden and generate periods of market exclusivity. In the near term, HAVN Life will be focused on substantiating the patent application with data from animal model and formulation studies and filing a Patent Cooperation Treaty application. The Company intends to launch the new drug within 4 years.
Acquisition Details
In consideration for the IP, the Company paid to Bolt Therapeutics $1,000,000 and issued: (i) 10,596,027 common shares, which shares will be subject to an escrow arrangement whereby one-sixth (1/6) of such shares will be released from escrow every three (3) months following completion of the Acquisition; and (ii) 5,298,013 common shares upon the satisfaction of certain milestones in respect of the IP.
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer
About HAVN Life Sciences Inc.
HAVN Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural health products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.
Connect
Investor Relations
ir@havnlife.com
(604) 687-7130
Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife
Media Contact
savi@emergence-creative.com
(647) 896-8078